-
Freedom Capital Markets Starts Enovis Corp (ENOV) at Buy
-
Enovis Corporation (ENOV) Tops Q3 EPS by 10c; offers guidance
-
Enovis Corp (ENOV) PT Lowered to $58 at Canaccord Genuity
-
Enovis Corp (ENOV) PT Lowered to $49 at Needham
-
Enovis Corp (ENOV) PT Lowered to $44 at Evercore ISI
-
Jehoshaphat Research is Short Enovis Corporation (ENOV)
-
Enovis Corp (ENOV) PT Lowered to $70 at Canaccord Genuity
-
Enovis Corp (ENOV) PT Lowered to $55 at Citizens JMP
-
Enovis Corporation (ENOV) Tops Q1 EPS by 7c ; Offers Guidance
-
Canaccord Genuity Reiterates Buy Rating on Enovis Corp (ENOV)
-
Evercore Adds 7 Names to Tactical Outperform List
-
Enovis Corporation (ENOV) Appoints Damien McDonald as CEO
-
Enovis Corporation (ENOV) Announces Planned CEO Change
-
Enovis Corporation (ENOV) Announces Leadership Change
-
Maplebear (CART) Set to Join S&P MidCap 400; Enovis (ENOV) to Join S&P SmallCap 600
-
Enovis Corporation (ENOV) to Join S&P SmallCap 600
-
Instacart (CART) to Join S&P MidCap 400
-
Needham Reiterates Buy Rating on Enovis Corp (ENOV)
-
JMP Securities Starts Enovis Corp (ENOV) at Market Outperform
-
Enovis Corporation (ENOV) Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
-
Enovis Corporation (ENOV) Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR Cones to EMPOWR Revision Knee
-
Enovis Corporation (ENOV) Tops Q2 EPS by 3c, provides guidance
-
JPMorgan Starts Enovis Corp (ENOV) at Neutral

